Clinical Trial

Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)

Study acronym: SCD-CARRE
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 3, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/hospital visits) or resulting in death over 12 months as compared with standard of care.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-05-31 -> 2026-07-31 2026-06-04
minor Completion pushed: 2026-05-31 -> 2026-07-31 2026-06-04
Trial Details
NCT Number NCT04084080
Lead Sponsor University of Pittsburgh
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Sickle Cell Disease
Enrollment 173 participants
Start Date 2020-02-26
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-03